Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Blueprint Medicines
Blueprint Medicines
(BPMC)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Ayvakit
Avapritinib
2020-01-09
2034
Gastrointestinal stromal tumors
Ayvakyt
Avapritinib
2020-09-24
2034
Gastrointestinal stromal tumors
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Avapritinib
neoplasms
,
systemic mastocytosis
,
mastocytosis
,
hematologic neoplasms
,
mast-cell leukemia
,
central nervous system neoplasms
,
gastrointestinal stromal tumors
Bevifimod
carcinoma
,
neoplasms
,
non-small-cell lung carcinoma
,
lung neoplasms
,
respiratory tract diseases
,
lung diseases
,
respiratory tract neoplasms
,
bronchogenic carcinoma
,
adenocarcinoma
,
neoplasms by histologic type
,
neoplasms by site
,
bronchial neoplasms
,
thoracic neoplasms
,
nerve tissue neoplasms
,
brain neoplasms
,
phenylketonurias
Sugemalimab
carcinoma
,
hepatocellular carcinoma
,
liver neoplasms
Sti571
neoplasms
,
gastrointestinal stromal tumors
Bsc
systemic mastocytosis
,
mastocytosis
,
mast cell activation syndrome
,
mast cell activation disorders
Evidence
lung neoplasms
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use